Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25056204 | 0.90 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL25056405 | 0.87 | KMT2A (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL25056535 | 0.85 | TGFBR1 (0.30) | — | |
| SCHEMBL25056267 | 0.85 | JAK2 (0.36) | JAK2 | |
| SCHEMBL25637830 | 0.85 | TDP1 (0.36) | — | |
| SCHEMBL25056216 | 0.85 | ALOX15 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL25056319 | 0.83 | ACHE (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL25056484 | 0.83 | KMT2A (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL25056175 | 0.82 | KDM4E (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL25056148 | 0.79 | CYP11B1 (0.36) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4137484-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | JAK2 119/4885CYP11B1 2006/4885CYP11B2 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.